Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

TELA Bio (TELA) Preferred Shares Issued (2018 - 2019)

TELA Bio's quarterly Preferred Shares Issued came in at -$48000.0 in Q4 2019, down 101.83% year-on-year from $2.6 million in Q4 2018, and down 102.13% quarter-over-quarter from $2.3 million in Q3 2019.

TELA Bio has reported Preferred Shares Issued for 2 years, with the latest figure at -$48000.0 in Q4 2019.

  • For the quarter ending Q4 2019, Preferred Shares Issued fell 101.83% year-over-year to -$48000.0; the trailing twelve-month figure through Dec 2019 stood at $14.4 million (changed N/A YoY), and the FY2019 full-year result was $14.4 million, up 261.16% from the prior year.
  • Preferred Shares Issued for Q4 2019 stood at -$48000.0, down from $2.3 million in the prior quarter.
  • The five-year high for Preferred Shares Issued was $11.7 million in Q2 2019, with the low at -$48000.0 in Q4 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Shares Issued (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 TELA Bio 13.26 Mn -26.28 Mn 12.52 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2019 -48,000.00
Dec 31, 2019 -48,000.00
Sep 30, 2019 2.26 Mn
Sep 30, 2019 2.26 Mn
Jun 30, 2019 11.68 Mn
Jun 30, 2019 11.68 Mn
Mar 31, 2019 481,000.00
Mar 31, 2019 481,000.00
Dec 31, 2018 2.63 Mn
Dec 31, 2018 2.63 Mn